Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance
November 13, 2024 07:00 ET
|
Kamada Ltd.
Revenues for Third Quarter of 2024 were $41.7 Million, up 10% Year-over-Year; Nine Month 2024 Total Revenues were $121.9 Million, up 15% Year-over-YearThird Quarter 2024 Adjusted EBITDA of $8.8...
Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024
November 06, 2024 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for...
Kamada to Present at the Stifel 2024 Healthcare Conference
November 04, 2024 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for...
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston
September 23, 2024 07:00 ET
|
Kamada Ltd.
New Plasma Collection Center in Houston Now Open, with Planned Annual Collection Capacity of Approximately 50,000 Liters and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at...
Kamada Reports Strong Second Quarter and First Half 2024 Financial Results with Year-Over-Year 6-Month Top-Line Growth of 18% and a 68% Increase in Profitability
August 14, 2024 07:00 ET
|
Kamada Ltd.
Revenues for Second Quarter of 2024 were $42.5 Million, up 13% Year-over-Year; First Half 2024 Total Revenues were $80.2 Million, up 18% Year-over-YearSecond Quarter 2024 Adjusted EBITDA of $9.1...
Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024
August 07, 2024 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed...
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
May 08, 2024 07:00 ET
|
Kamada Ltd.
Revenues for First Quarter of 2024 were $37.7 Million, Representing a 23% Increase Year-over-YearFirst Quarter 2024 Adjusted EBITDA of $7.5 Million, Representing a 96% Increase Year-over-YearMomentum...
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
May 01, 2024 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed...
Kamada Issues 2024 CEO Letter to Shareholders
March 06, 2024 07:05 ET
|
Kamada Ltd.
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed...
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
March 06, 2024 07:00 ET
|
Kamada Ltd.
Total Revenues for Fiscal Year 2023 of $142.5 Million, Representing All-Time Record Annual Revenues and Up 10% Compared to Fiscal Year 2022Fiscal Year 2023 Adjusted EBITDA of $24.1 Million, Up 35%...